Statistiche di base
| CIK | 1614067 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aridis Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| November 14, 2024 |
ARDS / Aridis Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-ards093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aridis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 040334104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| June 27, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 24th, 2024 (the “Effective Date”), between Aridis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subje |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2024 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| February 14, 2024 |
ARDS / Aridis Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
ARDS / Aridis Pharmaceuticals, Inc. / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aridis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 040334104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| February 13, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.0001 per share, of Aridis Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit t |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2024 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commi |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| December 18, 2023 |
AMENDMENT TO THE ARIDIS PHARMACEUTICALS, INC. (the “Corporation”) Exhibit 3.1 AMENDMENT TO THE BYLAWS OF ARIDIS PHARMACEUTICALS, INC. (the “Corporation”) Section 2.6 of Article II of the Bylaws of the Corporation (the “Bylaws”), is hereby amended and restated in its entirety as follows: “2.6. Quorum. “Except as otherwise required by law, the holders of record representing 1/3 of the voting interest of the shares of stock of the Corporation entitled to be voted t |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Nam |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 3, 2023 |
Exhibit 99.1 Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., November 3, 2023 (Globe Newswire) - Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and dev |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commi |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Name of |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 7, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 21, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commis |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction (Commission (I. R. S. Empl |
|
| August 4, 2023 |
7,207,208 Shares of Common Stock Aridis Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-233601 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 14, 2022) 7,207,208 Shares of Common Stock Aridis Pharmaceuticals, Inc. This prospectus supplement updates, supersedes and amends certain information contained in the prospectus t dated December 14, 2022 (the “Original Prospectus”), relating to the resale offering of an aggregate of 7,2 |
|
| August 4, 2023 |
2,473,778 Shares of Common Stock Aridis Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-233601 PROSPECTUS SUPPLEMENT (To Prospectus Dated September 5, 2019) 2,473,778 Shares of Common Stock Aridis Pharmaceuticals, Inc. This prospectus supplement updates, supersedes and amends certain information contained in the prospectus supplement dated August 2, 2021 (the “Original Prospectus”), relating to the offering of an aggregate of 1,30 |
|
| August 3, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-272128 Prospectus 4,000,000 Shares of Common Stock 6,000,000 Pre-Funded Warrants to Purchase up to 6,000,000 Shares of Common Stock 10,000,000 Warrants to Purchase up to 10,000,000 Shares of Common Stock Up to 16,000,000 Shares of Common Stock underlying the Pre-Funded Warrants and Warrants Aridis Pharmaceuticals, Inc. We are offering 4,000,000 |
|
| July 31, 2023 |
Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 July 31, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius Re: Aridis Pharmaceuticals, Inc. Form S-1 File No. 333-272128 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as a |
|
| July 31, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 28, 2023. As filed with the U.S. Securities and Exchange Commission on July 28, 2023. Registration Statement No. 333-272128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 7 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARIDIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2641188 (State or other juris |
|
| July 26, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 26, 2023. As filed with the U.S. Securities and Exchange Commission on July 26, 2023. Registration Statement No. 333-272128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 6 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARIDIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2641188 (State or other juris |
|
| July 26, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ARIDIS PHARMACEUTICALS, INC. |
|
| July 21, 2023 |
Form of Securities Purchase Agreement Exhibit 10.39 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July , 2023, between Aridis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| July 21, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 21, 2023. As filed with the U.S. Securities and Exchange Commission on July 21, 2023. Registration Statement No. 333-272128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARIDIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2641188 (State or other juris |
|
| July 21, 2023 |
Exhibit 4.1 EXHIBIT A-2 COMMON STOCK PURCHASE WARRANT Aridis Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: July , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her |
|
| July 21, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ARIDIS PHARMACEUTICALS, INC. |
|
| July 20, 2023 |
Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 July 20, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius Re: Aridis Pharmaceuticals, Inc. Form S-1 File No. 333-272128 Ladies and Gentlemen: Aridis Pharmaceuticals, Inc. (the “Company”) hereby respectfully withdraws its request, dated Ju |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 19, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 17, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| July 17, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 17, 2023. As filed with the U.S. Securities and Exchange Commission on July 17, 2023. Registration Statement No. 333-272128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARIDIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2641188 (State or other juris |
|
| July 17, 2023 |
As filed with the U.S. Securities and Exchange Commission on July 17, 2023. As filed with the U.S. Securities and Exchange Commission on July 17, 2023. Registration Statement No. 333-272128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARIDIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2641188 (State or other juris |
|
| July 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ARIDIS PHARMACEUTICALS, INC. |
|
| July 17, 2023 |
Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 July 17, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius Re: Aridis Pharmaceuticals, Inc. Form S-1 File No. 333-272128 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as a |
|
| July 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ARIDIS PHARMACEUTICALS, INC. |
|
| June 27, 2023 |
Form of Securities Purchase Agreement Exhibit 10.39 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between Aridis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s |
|
| June 27, 2023 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT Aridis Pharmaceuticals, Inc. Warrant Shares: Issue Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (as define |
|
| June 27, 2023 |
Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212. |
|
| June 27, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 27, 2023. As filed with the U.S. Securities and Exchange Commission on June 27, 2023. Registration Statement No. 333-272128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARIDIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2641188 (State or other juris |
|
| June 27, 2023 |
Exhibit 4.2 PREFUNDED COMMON STOCK PURCHASE WARRANT Aridis Pharmaceuticals, Inc. Warrant Shares: Initial Exercise Date: , 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 16, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissio |
|
| June 9, 2023 |
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update Exhibit 99.1 Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update LOS GATOS, Calif., June 8, 2023 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its first |
|
| June 9, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 9, 2023. As filed with the U.S. Securities and Exchange Commission on June 9, 2023. Registration Statement No. 333-272128 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARIDIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2641188 (State or other jurisd |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Name of |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 21, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissio |
|
| May 25, 2023 |
Letter from Baker Tilly US, LLP dated May 24, 2023 Exhibit 16.1 |
|
| May 22, 2023 |
Power of Attorney (included on signature page) As filed with the U.S. Securities and Exchange Commission on May 22, 2023. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARIDIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2641188 (State or other jurisdiction of incorporation o |
|
| May 22, 2023 |
Exhibit 21.1 List of Subsidiaries of Aridis Pharmaceuticals, Inc.: Name Jurisdiction of Incorporation/Formation Aridis Biopharmaceuticals LLC Delaware Aridis Pharmaceuticals C.V. Netherlands |
|
| May 22, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Aridis Pharmaceuticals, Inc. |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-38630 Aridis Pharmace |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-38630 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR ☐ |
|
| May 9, 2023 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commiss |
|
| May 1, 2023 |
Exhibit 10.1 Note Purchase And Loan Restructuring Agreement This Note Purchase and Loan Restructuring Agreement (this “Agreement”), dated as of April 26, 2023, is entered into by and among Aridis Pharmaceuticals, Inc., a Delaware corporation (“ARDS Inc.”), Aridis Biopharmaceuticals, LLC, a Delaware limited liability company (“ARDS LLC”), Aridis Pharmaceuticals, C.V., a Netherlands partnership (“AR |
|
| May 1, 2023 |
Exhibit 10.2 Security Agreement This Security Agreement (this “Agreement”), dated as of April 26, 2023, is executed by Aridis Pharmaceuticals, Inc., a Delaware corporation (“ARDS Inc.”), Aridis Biopharmaceuticals, LLC, a Delaware limited liability company (“ARDS LLC”), and Aridis Pharmaceuticals, C.V., a Netherlands partnership (“ARDS CV,” and together with ARDS Inc. and ARDS LLC, “Debtor”), in fa |
|
| May 1, 2023 |
Exhibit 4.1 SECURED PROMISSORY NOTE Up to $9,286,770.80 April 26, 2023 FOR VALUE RECEIVED, Aridis Pharmaceuticals, Inc., a Delaware corporation (“Aridis”), Aridis Pharmaceuticals, C.V., a Netherlands partnership (“ARDS CV”), and Aridis Biopharmaceuticals, LLC, a Delaware limited liability company (“ARDS LLC” and, together with Aridis and ARDS CV, “Borrower”), jointly and severally promise to pay i |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 19, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commiss |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-38630 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form N-SAR |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 27, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commiss |
|
| March 29, 2023 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 20, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commiss |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commiss |
|
| March 20, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.0001 per share, of Aridis Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. March 20, 2023 LIND GLOBAL FUND II LP By: Lind Global Partners |
|
| March 20, 2023 |
ARDS / Aridis Pharmaceuticals Inc / Lind Global Fund II LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aridis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 040334104 (CUSIP Number) March 16, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| March 16, 2023 |
6,000,000 Shares of Common Stock Aridis Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-267279 PROSPECTUS SUPPLEMENT (To Prospectus Dated September 12, 2022) 6,000,000 Shares of Common Stock Aridis Pharmaceuticals, Inc. We are offering an aggregate of 6,000,000 shares of our common stock, par value $0.0001 per share (the “Common Stock”), to two institutional investors. The purchase price of each share of Common Stock is $0.38. We |
|
| March 15, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 14, 2023, between Aridis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 14, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of (Commission (I. R. S. E |
|
| March 15, 2023 |
Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock Exhibit 99.1 Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock Los Gatos, Calif., March 14, 2023 – Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,000,000 shares of the Company’s common stock at a purchase price of $0.38 pe |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2023 |
ARDS / Aridis Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2023 |
ARDS / Aridis Pharmaceuticals Inc / ASTRAZENECA PLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aridis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 040334104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| December 19, 2022 |
ARDS / Aridis Pharmaceuticals Inc / Cystic Fibrosis Foundation - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Aridis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 040334104 (CUSIP Number) December 8, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| December 15, 2022 |
7,207,208 Shares Common Stock Aridis Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-268701 PROSPECTUS 7,207,208 Shares Common Stock Aridis Pharmaceuticals, Inc. This prospectus relates to the resale by a certain selling stockholder of Aridis Pharmaceuticals, Inc. (?Aridis,? the ?Company,? ?we,? ?our,? or ?us?) identified in this prospectus of up to 7,207,208 shares (the ?Resale Shares?) of common stock, par value $0.0001 per s |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 7, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commi |
|
| December 12, 2022 |
Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 December 12, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: Aridis Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-268701 Filed December 7, 2022 Ladies and Gentlemen: Pursuant t |
|
| December 12, 2022 |
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation Exhibit 99.1 Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation Los Gatos, Calif., December 12, 2022 – Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of AR-501, an inhalable br |
|
| December 12, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is entered into as of December , 2022 (the “Effective Date”), by and between Aridis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature pages hereto (the “Subscriber”). WHEREAS: The Company desires to issue and sell to the Subscriber, and the Sub |
|
| December 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ARIDIS PHARMACEUTICALS, INC. |
|
| December 7, 2022 |
As filed with the U.S. Securities and Exchange Commission on December 7, 2022. As filed with the U.S. Securities and Exchange Commission on December 7, 2022. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARIDIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2641188 (State or other jurisdiction of incorporati |
|
| December 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) ARIDIS PHARMACEUTICALS, INC. |
|
| December 6, 2022 |
As filed with the Securities and Exchange Commission on December 6, 2022 As filed with the Securities and Exchange Commission on December 6, 2022 Registration No. |
|
| November 22, 2022 |
Exhibit 99.1 Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year LOS GATOS, Calif., November 21, 2022 /GlobeNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of no |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 21, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Nam |
|
| November 15, 2022 |
NT 10-Q 1 formnt10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-38630 NOTIFICATION OF LATE FILING ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Trans |
|
| October 6, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-267279 Prospectus Supplement (To Prospectus Dated September 12, 2022) 1,800,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 5,407,208 Shares of Common Stock Aridis Pharmaceuticals, Inc. We are offering an aggregate of 1,800,000 shares of our common stock, par value $0.0001 per share (the ?Common Stock?) and pre-funded warrants |
|
| October 5, 2022 |
Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT ARIDIS PHARMACEUTICALS, INC. Warrant Shares: 5,407,208 Issue Date: October 7, 2022 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| October 5, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 29, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Com |
|
| October 5, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 5, 2022, between Aridis Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and the purchaser identified on the signature pages hereto (including its successors and assigns, the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and |
|
| October 5, 2022 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 5, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commis |
|
| September 26, 2022 |
Subject To Completion, Dated September 26, 2022 Filed Pursuant to Rule 424(b)(5) Registration No. 333-267279 The information contained in this preliminary prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus supplement is not an offer to sell these securities and it is not soliciting |
|
| September 8, 2022 |
Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 September 8, 2022 Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 September 8, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Aridis Pharmaceuticals, Inc. Form S-3 File No. 333-267279 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, |
|
| September 2, 2022 |
As filed with the U.S. Securities and Exchange Commission on September 2, 2022 As filed with the U.S. Securities and Exchange Commission on September 2, 2022 Registration No. 333-[] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 47-2641188 (State or other jurisdiction of incorporation or organiz |
|
| September 2, 2022 |
Form of Subordinated Indenture Exhibit 4.4 ARIDIS PHARMACEUTICALS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Ce |
|
| September 2, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) ARIDIS PHARMACEUTICALS, INC. |
|
| September 2, 2022 |
Exhibit 4.3 ARIDIS PHARMACEUTICALS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee?s Certificat |
|
| August 16, 2022 |
Exhibit 99.1 Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., August 16, 2022 /PRNewswire/ ? Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infe |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-38630 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form N-SAR ? T |
|
| August 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commis |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Name of |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 15, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commis |
|
| June 27, 2022 |
Letter from Mayer Hoffman McCann P.C. dated June 27, 2022 Exhibit 16.1 June 27, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of Aridis Pharmaceuticals, Inc.?s Form 8-K dated June 27, 2022, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained in Item 4 |
|
| June 27, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 21, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| June 6, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissio |
|
| May 16, 2022 |
Exhibit 99.1 Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif., May 16, 2022 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 16, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissio |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 19, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 15, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 13, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commiss |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 13, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Aridis Pharmaceuticals, Inc.: Name Jurisdiction of Incorporation/Formation Aridis Biopharmaceuticals LLC ? Delaware Aridis Pharmaceuticals C.V. ? Netherlands ? |
|
| April 1, 2022 |
Exhibit 99.1 Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update Awarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 LOS GATOS, Calif., March 31, 2022 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharma |
|
| April 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 31, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commiss |
|
| March 30, 2022 |
NT 10-K 1 tm2210814d1nt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-38630 NOTIFICATION OF LATE FILING x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2021 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form |
|
| February 14, 2022 |
ARDS / Aridis Pharmaceuticals Inc / Francis Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Aridis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 040334104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 19, 2022 |
EX-1.1 2 tm223211d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution Version ARIDIS PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.0001 per share) At-the-Market Sales Agreement January 19, 2022 Virtu Americas LLC One Liberty Plaza 165 Broadway New York, NY 10006 Ladies and Gentlemen: Aridis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 19, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commi |
|
| January 19, 2022 |
Up to $25,000,000 Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-233601? PROSPECTUS SUPPLEMENT (To Prospectus Dated September 5, 2019) Up to $25,000,000 Common Stock We have entered into an At-the-Market Sales Agreement, or the Sales Agreement with Virtu Americas LLC, or Virtu, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In |
|
| January 5, 2022 |
EX-99.1 2 tm221658d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 1 Innovative Therapeutics For Respiratory Health Investor Presentation 1Q-2022 2 Forward Looking Statement These forward-looking statements relate to future events or future financial performance of the Company. All such forward-looking statements involve risks and uncertainties and are not guaranties of future performance. An investment in |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2022 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commis |
|
| December 21, 2021 |
Exhibit 99.1 Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses AR-701 cocktail binds to the Omicron variant with similar effectiveness as to the original Wuhan strain Viral neutralization and animal infection models support broad prophyl |
|
| December 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 21, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| November 30, 2021 |
Exhibit 4.1 SECURED PROMISSORY NOTE #1 Effective Date: November 23, 2021 U.S. $5,250,000.00 FOR VALUE RECEIVED, Aridis Pharmaceuticals, Inc., a Delaware corporation (?Borrower?), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (?Lender?), $5,250,000.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is |
|
| November 30, 2021 |
Exhibit 10.2 Security Agreement This Security Agreement (this ?Agreement?), dated as of November 23, 2021, is executed by Aridis Pharmaceuticals, Inc., a Delaware corporation (?Debtor?), in favor of Streeterville Capital, LLC, a Utah limited liability company (?Secured Party?). A. Debtor has issued to Secured Party a certain Secured Promissory Note #1 of even date herewith, as may be amended from |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 23, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| November 30, 2021 |
Exhibit 10.1 Note Purchase Agreement This Note Purchase Agreement (this ?Agreement?), dated as of November 23, 2021, is entered into by and between Aridis Pharmaceuticals, Inc., a Delaware corporation (?Company?), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (?Investor?). A. Company and Investor are executing and delivering this Agreement in relia |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 10, 2021 |
Exhibit 99.1 Aridis Pharmaceuticals Announces Third Quarter 2021 Results Executed AstraZeneca in-licensing deal of Phase 3-ready antibody, suvratoxumab, in July 2021 Bolstered financial position with approx. $25 million in equity financing in August 2021 LOS GATOS, Calif., November 10, 2021 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the disco |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| August 27, 2021 |
The date of this prospectus is August 26, 2021 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-258809 PROSPECTUS Aridis Pharmaceuticals, Inc. 884,956 Shares of Common Stock This prospectus relates to the resale by the selling stockholder named herein, or its pledgees, donees, transferees or other successors in interest, from time to time, of 884,956 shares (the ?Shares?) of our common stock, par value $0.0001 per share (the ?Common Stock |
|
| August 24, 2021 |
Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 Aridis Pharmaceuticals, Inc. 983 University Avenue, Bldg. B Los Gatos, CA 95032 August 24, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius Re: Aridis Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 13, 2021 File No. 333-258809 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and |
|
| August 23, 2021 |
As filed with the Securities and Exchange Commission on August 23, 2021 As filed with the Securities and Exchange Commission on August 23, 2021 Registration No. |
|
| August 13, 2021 |
Power of Attorney (included on signature page) As filed with the Securities and Exchange Commission on August 13, 2021 Registration No. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commis |
|
| August 12, 2021 |
Aridis Pharmaceuticals, Inc. Consolidated Balance Sheets (in thousands) Exhibit 99.1 Aridis Pharmaceuticals Announces Second Quarter 2021 Results ? In-licensed Phase 3-ready antibody, suvratoxumab, from AstraZeneca ? Raised approximately $25 million in equity financing ? Confirmed that SARS-CoV-2 antibody combination AR-712 is active against the Delta variant and all other strains on the CDCs Variants of Interest and Variants of Concern lists LOS GATOS, Calif., August |
|
| August 12, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of in |
|
| August 12, 2021 |
Aridis Pharmaceuticals, Inc. Consolidated Balance Sheets (in thousands) Exhibit 99.1 Aridis Pharmaceuticals Announces Second Quarter 2021 Results ? In-licensed Phase 3-ready antibody, suvratoxumab, from AstraZeneca ? Raised approximately $25 million in equity financing ? Confirmed that SARS-CoV-2 antibody combination AR-712 is active against the Delta variant and all other strains on the CDCs Variants of Interest and Variants of Concern lists LOS GATOS, Calif., August |
|
| August 12, 2021 |
Exhibit 10.3 AMENDMENT NO. 1 TO LICENSE AGREEMENT This Amendment No. 1 to the License Agreement between MedImmune Limited and Aridis Pharmaceutitcals, Inc. (the ?Amendment?) is entered into as 09 August 2021 (the ?Amendment Effective Date?), by and between: (1) MedImmune Limited, a company incorporated in England under No. 2451177 whose registered office is at Milstein Building, Granta Park, Cambr |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 4, 2021 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT Aridis Pharmaceuticals, Inc. Warrant Shares: Issue Date: Initial Exercise Date: THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above |
|
| August 4, 2021 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-233601? PROSPECTUS SUPPLEMENT (To Prospectus Dated September 5, 2019) 1,300,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,647,556 Shares of Common Stock Warrants to Purchase up to 2,473,778 Shares of Common Stock Up to 6,121,334 Shares of Common Stock underlying such Pre-Funded Warrants and Warrants Aridis |
|
| August 4, 2021 |
Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Aridis Pharmaceuticals, Inc. Warrant Shares: Issue Date: Initial Exercise Date: THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| August 4, 2021 |
Exhibit 99.1 Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced At a Premium to Market LOS GATOS, Calif., August 2, 2021 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered into a definit |
|
| August 4, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 2, 2021, between Aridis Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and condi |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 2, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of (Commission File Number |
|
| July 27, 2021 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the common stock, par value $0. |
|
| July 27, 2021 |
ARDS / Aridis Pharmaceuticals Inc / ASTRAZENECA PLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aridis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 040334104 (CUSIP Number) July 20, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| July 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 26, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| July 26, 2021 |
EX-99.1 2 tm2123222d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aridis Pharmaceuticals’ COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC) CoVIC’s animal efficacy data shows that Aridis’ AR-711 mAb is among the top 5 most potent out of more than 350 COVID mAbs that have entered the CoVIC evaluation program to date The dual mAbs co |
|
| July 19, 2021 |
EX-10.1 2 tm2122496d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version *Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed LICENSE AGREEMENT between MEDIMMUNE LIMITED and ARIDIS PHARMACEUTICALS, INC Dated as of 12 July 2021 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 ARTICLE 2 |
|
| July 19, 2021 |
EX-99.1 3 tm2122496d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca Los Gatos, Calif., July 19, 2021 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to i |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 13, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| July 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 12, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| July 13, 2021 |
EX-99.1 2 tm2122085d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-COV2 Delta Variant Texas Biomedical Research Institute and Aridis’ data confirmed AR-712 binds to and neutralizes the Delta variant of SARS-COV2 virus Binding analysis projects the ability of AR-712 to bind to all variants on the Center for Disease Control’s Variants of Interest and V |
|
| June 3, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissio |
|
| June 2, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissio |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 18, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissio |
|
| May 11, 2021 |
Aridis Pharmaceuticals, Inc. Consolidated Balance Sheets (in thousands) Exhibit 99.1 Aridis Pharmaceuticals Announces First Quarter 2021 Results LOS GATOS, Calif., May 11, 2021 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the first quarter ended March 31, 2021. Fir |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissio |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Name of |
|
| April 30, 2021 |
Quarterly Report - FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark one) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-3 |
|
| April 16, 2021 |
The Company’s Definitive Proxy Statement filed with the SEC on April 16, 2021; ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Aridis Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 040334104 (CUSIP Number) March 17, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| March 31, 2021 |
Exhibit 99.1 Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update LOS GATOS, Calif., March 30, 2021 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results f |
|
| March 31, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commiss |
|
| March 30, 2021 |
Subsidiaries of the Registrant ? Exhibit 21.1? List of Subsidiaries of Aridis Pharmaceuticals, Inc.: Name ? ? Jurisdiction of Incorporation/Formation ? Aridis Biopharmaceuticals LLC ? ? Delaware ? Aridis Pharmaceuticals C.V. ? ? Netherlands ? |
|
| March 30, 2021 |
TABLE OF CONTENTS ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 17, 2021 |
1,037,405 Shares of Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| March 16, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 15, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incor |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 15, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commiss |
|
| March 15, 2021 |
EX-10.1 2 a21-97861ex10d1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 15, 2021, between Aridis Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 983 University Avenue, Bldg. B, Los Gatos, CA 95032 (the “Company”), and each purchaser identified on the signature pages hereto (each, includin |
|
| March 8, 2021 |
Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode EX-99.1 2 tm218998d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aridis Enters into APEX™ Licensing and Product Discovery Agreement for Zoonotic Viruses with Kermode LOS GATOS, Calif., March 8, 2021 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. Kermode works on vaccines |
|
| March 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 8, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| February 23, 2021 |
EX-99.1 2 a21-76751ex99d1.htm EX-99.1 Exhibit 99.1 Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants National Institute of Allergy and Infectious Disease (NIAID) and the Coronavirus Immunotherapy Consortium (CoVIC) are providing preclinical services support to accelerate development Ph |
|
| February 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2021 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| February 12, 2021 |
ARIDIS PHARMACEUTICALS, INC. 983 University Avenue, Bldg. B Los Gatos, California 95032 ARIDIS PHARMACEUTICALS, INC. 983 University Avenue, Bldg. B Los Gatos, California 95032 February 12, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Rolf Sundwall Kevin Vaughn Re: Aridis Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed April 8, 2020 File No. 001-38630 Dear Ladies and Gentlemen: This |
|
| December 4, 2020 |
ARIDIS PHARMACEUTICALS, INC. 983 University Avenue, Bldg. B Los Gatos, California 95032 ARIDIS PHARMACEUTICALS, INC. 983 University Avenue, Bldg. B Los Gatos, California 95032 December 4, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Rolf Sundwall Kevin Vaughn Re: Aridis Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed April 8, 2020 File No. 001-38630 Dear Ladies and Gentlemen: This l |
|
| November 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. (Exact Nam |
|
| November 23, 2020 |
Exhibit 10.5 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXCLUSIVE LICENSE AGREEMENT This exclusive license agreement (this “Agreement”) is made and is effective as of September 10, 2020 (the “Effective Date”) between The UAB Research Foundation (“UABRF”), a non-profit |
|
| November 20, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 20, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| November 20, 2020 |
Aridis Pharmaceuticals Announces Third Quarter 2020 Results Exhibit 99.1 Aridis Pharmaceuticals Announces Third Quarter 2020 Results SAN JOSE, Calif., November 20, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the third quarter ended September 30, 2 |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 001-38630 NOTIFICATION OF LATE FILING o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2020 o Transition Report on Form 10-K o Transition Report on Form 10-Q o Transition Report on Form 20-F o Transition Report on Form N-SA |
|
| October 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 14, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commi |
|
| October 20, 2020 |
Exhibit 10.1 NNN OFFICE LEASE BOCCARDO CORPORATION, a California corporation as “Landlord” and ARIDIS PHARMACEUTICALS, INC. as “Tenant” ARIDIS PHARMACEUTICALS, INC. NNN OFFICE LEASE SUMMARY OF BASIC LEASE TERMS SECTION (LEASE REFERENCE) TERMS A. (Introduction) Lease Reference Date: October 6, 2020 B. (Introduction) Landlord: BOCCARDO CORPORATION, a California corporation C. (Introduction) Tenant: |
|
| October 19, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 19, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commi |
|
| October 19, 2020 |
Exhibit 99.1 Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients SAN JOSE, Calif., October 19, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life |
|
| October 15, 2020 |
1,134,470 Shares of Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| October 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 13, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commi |
|
| October 14, 2020 |
Exhibit 99.1 Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering Company Enters Into Securities Purchase Agreement with Institutional Investors SAN JOSE, Calif., October 14, 2020 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the “Company”), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threate |
|
| October 14, 2020 |
Exhibit 10.3 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER ( |
|
| October 14, 2020 |
Exhibit 10.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER ( |
|
| October 14, 2020 |
EX-10.1 3 tm2033155d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of October 13, 2020, is by and among Aridis Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 5941 Optical Ct., San Jose, CA 95138 (the ”Company”), and the buyers identified on the signature pages hereto (the “Buyers”). REC |
|
| September 1, 2020 |
ARIDIS PHARMACEUTICALS, INC. 5941 Optical Ct. San Jose, CA 95138 ARIDIS PHARMACEUTICALS, INC. 5941 Optical Ct. San Jose, CA 95138 September 1, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Rolf Sundwall Kevin Vaughn Re: Aridis Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed April 8, 2020 File No. 001-38630 Dear Ladies and Gentlemen: This letter sets forth respo |
|
| August 18, 2020 |
ARIDIS PHARMACEUTICALS, INC. 5941 Optical Ct. San Jose, CA 95138 ARIDIS PHARMACEUTICALS, INC. 5941 Optical Ct. San Jose, CA 95138 August 18, 2020 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Rolf Sundwall Kevin Vaughn Re: Aridis Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed April 8, 2020 File No. 001-38630 Dear Ladies and Gentlemen: This letter sets forth respons |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commis |
|
| August 11, 2020 |
Aridis Pharmaceuticals Announces Second Quarter 2020 Results Exhibit 99.1 Aridis Pharmaceuticals Announces Second Quarter 2020 Results SAN JOSE, Calif., August 11, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the second quarter ended June 30, 2020. |
|
| July 28, 2020 |
As filed with the Securities and Exchange Commission on July 27, 2020 Registration No. |
|
| June 26, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 25, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| June 26, 2020 |
EX-99.1 2 a20-235581ex99d1.htm EX-99.1 Exhibit 99.1 Novel Anti-infectives Focusing on Respiratory Health APEXTM mAb Discovery Platform Cantor Fitzgerald Fireside Chat 25June2020 Aridis Pharmaceuticals 1 Forward-Looking Statements These forward-looking statements relate to future events or future financial performance of the Company. All such forward-looking statements involve risks and uncertainti |
|
| June 22, 2020 |
Exhibit 99.1 Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial · Phase 1 portion of the Phase 1/2a trial, 48 healthy volunteers were treated with either single or multiple weekly dose regimens · No serious adverse events and well tolerated · AR-501 Phase 2a received recommendations to proceed from the Data Safety Monitoring Board (DSMB) fr |
|
| June 22, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 22, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| June 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| June 15, 2020 |
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer Exhibit 99.1 Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer SAN JOSE, Calif., June 15, 2020 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has appointed Dr. Hasan Jafri as Chief Medical |
|
| June 4, 2020 |
Submission of Matters to a Vote of Security Holders 8-K 1 a20-2185218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction o |
|
| May 14, 2020 |
Up to $22,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-233601 PROSPECTUS SUPPLEMENT (To Prospectus Dated September 5, 2019) Up to $22,000,000 Common Stock We previously entered into a certain Controlled Equity OfferingSM sales agreement, or the sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, acting as sales agent, having an aggregate offering price of up to $25,000,000. As of M |
|
| May 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissio |
|
| May 12, 2020 |
Aridis Pharmaceuticals Announces First Quarter 2020 Results Exhibit 99.1 Aridis Pharmaceuticals Announces First Quarter 2020 Results SAN JOSE, Calif., May 12, 2020 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate results for the first quarter ended March 31, |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. |
|
| May 5, 2020 |
Silicon Valley Bank U.S. Small Business Administration Paycheck Protection Program Exhibit 99.1 Silicon Valley Bank U.S. Small Business Administration Paycheck Protection Program Note SBA Loan No. 56951872-07 SBA Loan Name Borrower Aridis Pharmaceuticals, Inc. Legal Name DBA Date 5/1/2020 Loan Amount $714510 Interest Rate 1.0% per annum Borrower Aridis Pharmaceuticals, Inc. Operating Company Not applicable Lender Silicon Valley Bank 1. PROMISE TO PAY. In return for the Loan, Bor |
|
| May 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commission |
|
| April 17, 2020 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 8, 2020 |
ARDS / Aridis Pharmaceuticals, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on April 8, 2020 Registration No. |
|
| April 8, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 8, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| April 8, 2020 |
ARDS / Aridis Pharmaceuticals, Inc. 10-K - Annual Report - 10-K Use these links to rapidly review the document TABLE OF CONTENTS PART IV CONSOLIDATED FINANCIAL STATEMENTS ARIDIS PHARMACEUTICALS, INC. |
|
| April 8, 2020 |
Subsidiaries of the Registrant QuickLinks - Click here to rapidly navigate through this document Exhibit 21.1 List of Subsidiaries of Aridis Pharmaceuticals, Inc.: Name Jurisdiction of Incorporation/Formation Aridis Biopharmaceuticals LLC Delaware Aridis Pharmaceuticals C.V. Netherlands Shenzhen Arimab BioPharmaceuticals Co., Ltd. People's Republic of China QuickLinks Exhibit 21.1 |
|
| April 8, 2020 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Aridis Pharmaceuticals, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) common stock, $0.0001 par value per share (“Common Stock”). Unless the context otherw |
|
| April 8, 2020 |
EX-99.1 2 a20-152871ex99d1.htm EX-99.1 Exhibit 99.1 Aridis Pharmaceuticals Announces 2019 Fourth Quarter and Year-End Financial Results and Business Update SAN JOSE, Calif., April 8, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, t |
|
| March 30, 2020 |
ARDS / Aridis Pharmaceuticals, Inc. NT 10-K - - NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Commission File Number: 001-38630 NOTIFICATION OF LATE FILING (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2019 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report |
|
| March 6, 2020 |
Aridis Pharmaceuticals to Postpone Investor Day Due to Coronavirus Concerns Exhibit 99.1 Aridis Pharmaceuticals to Postpone Investor Day Due to Coronavirus Concerns SAN JOSE, Calif., March 6, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the postponement of its Investor Day scheduled for T |
|
| March 6, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 a20-1200418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 6, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction |
|
| March 5, 2020 |
Aridis Pharmaceuticals to Present at the 32nd Annual ROTH Conference Exhibit 99.1 Aridis Pharmaceuticals to Present at the 32nd Annual ROTH Conference SAN JOSE, Calif., March 5, 2020 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that Vu Truong, Ph.D., Chief Executive Officer, will presen |
|
| March 5, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 tm2011678-28k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 5, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdi |
|
| March 4, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 4, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commissi |
|
| March 4, 2020 |
Exhibit 99.1 Aridis Pharmaceuticals Provides Update on Investor Day Featuring Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia SAN JOSE, Calif., March 4, 2020 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, is pleased to provid |
|
| January 28, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 tm206081d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 28, 2020 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other juris |
|
| January 28, 2020 |
EX-99.1 2 tm206081d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Aridis Pharmaceuticals Presents APEXTM Antibody Discovery and Production Platform Technology at the 19th Annual CHI PepTalk Conference SAN JOSE, Calif., Jan. 28th, 2020 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the “Company”) presented a comprehensive profile of its APEXTM platform technology at the antibody and cell engine |
|
| January 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2019 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| January 2, 2020 |
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer Exhibit 99.1 Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer SAN JOSE, Calif., January 2, 2020 /PRNewswire/ - Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, today announced the appoi |
|
| December 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 30, 2019 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| November 13, 2019 |
ARDS / Aridis Pharmaceuticals, Inc. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38630 Aridis Pharmaceuticals, Inc. |
|
| November 13, 2019 |
Aridis Pharmaceuticals Announces Third Quarter 2019 Results Exhibit 99.1 Aridis Pharmaceuticals Announces Third Quarter 2019 Results SAN JOSE, Calif., November 13, 2019 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, today reported financial and corporate |
|
| November 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2019 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Comm |
|
| October 11, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 9, 2019 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Commis |
|
| October 11, 2019 |
Exhibit 99.1 Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer SAN JOSE, Calif., October 11, 2019 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has app |
|
| October 2, 2019 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of September 27th, 2019 (the “Effective Date”) by and between AR |
|
| October 2, 2019 |
Exhibit 99.1 Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology SAN JOSE, Calif., September 30, 2019 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-thre |
|
| October 2, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 27, 2019 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdiction of incorporation) (Com |
|
| September 27, 2019 |
Aridis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference Exhibit 99.1 Aridis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference SAN JOSE, Calif., September 27, 2019 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that Vu Truong, Ph.D., Chief Executive Of |
|
| September 27, 2019 |
Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek™ 2019 EX-99.2 3 a19-191451ex99d2.htm EX-99.2 Exhibit 99.2 Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek™ 2019 SAN JOSE, Calif., September 27, 2019 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced |
|
| September 27, 2019 |
Financial Statements and Exhibits, Other Events 8-K 1 a19-1914518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 27, 2019 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdic |
|
| September 9, 2019 |
Exhibit 99.1 Aridis Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019 SAN JOSE, Calif., September 8, 2019 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that |
|
| September 9, 2019 |
Financial Statements and Exhibits, Other Events 8-K 1 a19-1843318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 8, 2019 Aridis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38630 47-2641188 (State or other jurisdict |
